Antidotes and Management of Anticoagulant Rodenticide Poisoning

Immediate Reversal for Severe Bleeding (Life‑Threatening)

• Administer prothrombin complex concentrate (PCC) 25–50 IU/kg together with intravenous vitamin K₁ 10 mg (or 100 µg/kg in children) to achieve rapid coagulopathy reversal and lower mortality in patients with severe bleeding from long‑acting anticoagulant rodenticide (LAAR) poisoning. 1, 2, 3
• PCC is superior to fresh frozen plasma (FFP) for fast INR correction and for reducing hematoma expansion, especially in intracranial hemorrhage. 1, 3
• The combination of PCC and vitamin K₁ cuts mortality by approximately 50 % compared with vitamin K₁ alone in severe bleeding cases. 1
• When active bleeding is present with INR > 1.5 (or > 1.2 for intracranial bleeding), reversal should be initiated immediately without waiting for laboratory INR results. 1, 2
• If PCC is unavailable, recombinant factor VIIa (1.2–4.8 mg or 90 µg/kg) can be used as an alternative reversal agent. 3
• FFP requires large volumes (>30 mL/kg) and is less effective than PCC for rapid correction; therefore it should not be used as first‑line therapy. 1, 3

Management of Non‑Severe Bleeding or Asymptomatic Coagulopathy

• For patients with an elevated INR but no severe bleeding, give vitamin K₁ alone (10 mg IV or oral, chosen according to urgency). 1, 2, 4
• Intravenous vitamin K₁ 10 mg infused slowly provides faster INR correction than oral dosing; the risk of anaphylaxis is rare (≈3 per 10 000 administrations). 1, 3
• Oral vitamin K₁ is preferred when feasible because it carries a lower anaphylaxis risk. 3
• In asymptomatic overdose with INR 6–10, administer 2 mg oral vitamin K₁. 4
• In asymptomatic overdose with INR > 10, administer 5 mg oral vitamin K₁. 4

Monitoring and Follow‑Up

• Check INR 30 minutes after reversal, then at 6–8 hours and again at 24 hours to identify rebound coagulopathy and guide additional PCC or vitamin K₁ dosing. 1, 2
• INR rebound is linked to a higher risk of recurrent bleeding. 3

Adjunctive Therapies

• Activated charcoal may be given if LAAR ingestion occurred within 8 hours, but its administration must not delay transport to the emergency department. 5
• Charcoal can decrease LAAR absorption up to 8 hours post‑ingestion by interrupting enterohepatic recirculation. 5
• Charcoal is contraindicated in patients with altered consciousness. 5

Common Pitfalls to Avoid

• Do not use FFP as the initial reversal agent; its large volume requirement and inferior efficacy make PCC the preferred choice. 1, 3
• Do not administer vitamin K₁ prophylactically before coagulopathy is documented.
• Do not discontinue vitamin K₁ therapy solely based on a normalized INR; serum LAAR concentrations should be measured to prevent recurrence.
• Subcutaneous vitamin K₁ should be avoided because it provides slower and less reliable correction compared with intravenous or oral routes. 6

Guideline for Hospital Monitoring and Reversal Therapy in Intentional Anticoagulant Rodenticide Ingestion

Initial Contact and Assessment

Hospital Monitoring Requirements

Management of Severe Active Bleeding

Management of Asymptomatic or Non‑Severe Cases

Vitamin K₁ Administration Considerations

Serial INR Monitoring After Reversal

Psychiatric Evaluation

Immediate Management of Anticoagulant Rodenticide Poisoning

1. Definition of Bleeding Severity

• Major/life‑threatening bleeding is defined as hemorrhage at critical sites (intracranial, intraspinal, intra‑ocular, pericardial, retro‑peritoneal), hemodynamic instability, a hemoglobin drop ≥ 2 g/dL, or the need for ≥ 2 units of packed red blood cells. The American College of Cardiology adopts this definition. 13
• Non‑severe bleeding comprises all other bleeding manifestations that do not meet the above criteria. Anaesthesia (2025) provides this classification. 14

2. Reversal Strategy for Life‑Threatening or Severe Bleeding

• Prothrombin complex concentrate (PCC) 25–50 IU/kg IV should be given immediately; for intracranial hemorrhage a dose of 50 IU/kg is recommended to achieve INR < 1.2. Anaesthesia (2025) endorses this dosing. 14
• Vitamin K₁ 10 mg IV (or 100 µg/kg in children) should be administered concurrently by slow infusion over 30 minutes. The American College of Cardiology cites this regimen. [15] [16]
• All anticoagulant and antiplatelet agents must be stopped to prevent further coagulopathy. The American College of Cardiology recommends cessation. 13
• Supportive care (local hemostatic measures, volume resuscitation, and blood transfusion as needed) is essential adjunctive therapy. The American College of Cardiology outlines these measures. 13

3. Management of Non‑Severe Bleeding or Asymptomatic Coagulopathy

• PCC or fresh‑frozen plasma (FFP) should NOT be used for asymptomatic overdose; vitamin K₁ monotherapy is sufficient. Anaesthesia (2025) advises against PCC/FFP in this setting. 17

• Route of vitamin K₁: IV provides faster INR correction (within 24 h) but carries a rare anaphylaxis risk (~3 per 10 000). Oral administration is preferred when feasible due to lower risk and reliable effect. Sub‑cutaneous injection is discouraged because of slow and unpredictable correction. The American College of Cardiology supplies these recommendations. [15] [16]

4. Critical Monitoring Protocol

• Serial INR checks are mandatory: at 30 minutes post‑reversal, again at 6–8 hours, and a final measurement at 24 hours. Anaesthesia (2025) specifies this schedule. 14
• INR rebound (rise after initial correction) signals a heightened risk of recurrent bleeding and may necessitate additional PCC or vitamin K₁. Anaesthesia (2025) highlights this warning. 14
• For dabigatran‑containing rodenticides (rare), plasma concentration should be measured 12–24 hours after reversal if the initial level exceeds 200 ng/mL. Anaesthesia (2025) recommends this monitoring. 14

5. Adjunctive Therapies

• Tranexamic acid may be administered according to the same indications used for patients without anticoagulation who are bleeding. Anaesthesia (2025) supports this practice. 14

Management of Elevated INR and Vitamin K Dosing

Immediate Reversal for Life‑Threatening or Major Bleeding

• Prothrombin complex concentrate (PCC) 25–50 IU/kg IV should be given as first‑line therapy; for intracranial hemorrhage the higher dose of 50 IU/kg is recommended to achieve INR < 1.2. 18
• Vitamin K₁ 10 mg IV (or 100 µg/kg in children) should be administered concurrently by slow infusion over ~30 min to maintain reversal beyond the ~4‑hour effect of PCC. 18
• PCC corrects INR within ≈ 3 minutes and is markedly superior to fresh‑frozen plasma, which requires large volumes (>30 mL/kg), corrects more slowly, and carries higher transfusion‑related risk. 18
• INR monitoring: check INR at 30 min after reversal, then at 6–8 h and 24 h to detect rebound coagulopathy that may necessitate additional PCC or vitamin K. 18

Vitamin K‑Only Strategy for Non‑Severe Bleeding or Asymptomatic Elevated INR

• Oral vitamin K is strongly preferred over subcutaneous (slow, unreliable) and intravenous (rare anaphylaxis ≈ 3 / 10 000). 18
• IV vitamin K should be reserved for patients unable to take oral medication or when rapid correction (within 6–12 h) is essential; it provides faster INR reduction than oral but carries a small anaphylaxis risk. 18

Evidence on Dosing Strategies

• A 2017 randomized trial showed individualized vitamin K dosing (based on index INR and body surface area) returned 68.9 % of patients to target INR within 24 h versus 52.8 % with fixed 1–2 mg doses (P = 0.026). Although statistically superior, fixed‑dose regimens remain guideline‑endorsed for bedside simplicity. 18
• A 2000 randomized study found that 0.5 mg IV vitamin K achieved an optimal INR response (2–4) in 67 % of patients with INR 7–9.5, whereas 1–2 mg doses often over‑corrected to INR < 2.0, suggesting lower IV doses are sufficient for moderate over‑anticoagulation without bleeding. 18

Pre‑Operative Management

• For elective surgery with mildly elevated INR (1.1–1.5), an INR ≤ 1.2 is acceptable even for high‑risk neurosurgical or neuraxial procedures; therefore routine vitamin K is unnecessary in most cases. 18
• The American College of Chest Physicians (2022) recommends against routine pre‑operative vitamin K when INR is 1.5–2.0 measured 1–2 days before surgery, citing concerns about delayed postoperative re‑anticoagulation and limited efficacy data. 19
• When vitamin K is administered pre‑operatively for INR 1.4–1.9, a 1 mg oral dose normalizes INR (≤ 1.3) in ≈ 77 % of patients by the day of surgery. 19

Monitoring and Pitfalls

• Do not use subcutaneous vitamin K; it provides the slowest and least reliable INR correction. 18
• Do not use fresh‑frozen plasma as first‑line reversal for urgent bleeding; PCC is faster, more effective, and safer. 18
• Do not give prophylactic vitamin K before documented coagulopathy; this can delay necessary procedures without proven benefit.
• Do not assume a higher dose (10 mg) is always better; while it reduces INR faster than 5 mg, it may prolong the time to re‑achieve therapeutic INR after warfarin is restarted. 18
• Do not stop INR monitoring after initial correction; rebound INR is associated with recurrent bleeding risk, so serial checks at 6–8 h and 24 h are essential. 18

Route‑Specific Administration Details

• Intravenous vitamin K should be infused ≤ 1 mg per minute to minimize anaphylaxis risk. 18
• IV vitamin K may be diluted in preservative‑free 0.9 % sodium chloride, 5 % dextrose, or a mixture of both; benzyl‑alcohol‑containing solutions are contraindicated in newborns. 18
• Oral vitamin K achieves INR correction within 24–48 h (dose‑ and baseline‑INR dependent) and is the preferred route for asymptomatic over‑anticoagulation due to safety and convenience. 18

Indications and Contraindications for Vitamin K Use in Bleeding Patients

INR Thresholds for Vitamin K Administration

Dosing Recommendations Based on INR Level

Management of Bleeding When INR Is Not Elevated

Recommended Regimen When Vitamin K Is Indicated

Risks of Unnecessary Vitamin K Administration